Company intelligence / Profile preview

CardioVascular BioTherapeutics, Inc.

Dallas, Texas, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

The company completed a Phase I trial for severe coronary heart disease with 21 patients at 6 U.S. sites, with Phase II trials planned for severe coronary heart disease, dermal wound healing, and peripheral artery disease[3]

Therapeutic areas: Men's HealthEndocrinologyCardiovascularNeurology
Modalities: Protein therapeutics
Industry: Biotech

Drug pipeline

3 assets

VT-141

Phase 2

Indications: Coronary artery disease, Diabetic foot ulcer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on CardioVascular BioTherapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardioVascular BioTherapeutics, Inc..

Explore the full profile